Gyre Therapeutics Reports Q3 2026 Revenue of $32.9 Million, Beating Estimates; GAAP EPS of $(0. ...
Commercial Sales Held Steady While Integration Costs and Pipeline Spending Drove a Quarterly Net Loss Related Stocks: GYRE ,
Commercial Sales Held Steady While Integration Costs and Pipeline Spending Drove a Quarterly Net Loss Related Stocks: GYRE ,